Amgen

Open: 276.27 Close: 276.17 Change: -0.1

Are you still looking for information about Amgen Stock? An AI summarized it for you.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, company, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen Inc. stock outperforms competitors despite losses on the day - marketwatch.com.com.

Today's News

Amgen Inc. stock outperforms competitors despite losses on the day - marketwatch.com. There are rarely this many stocks overbought — but usually its a good sign. Amgen (NASDAQ:AMGN) might deserve your attention today. Over the last three years, Amgen has grown EPS by 4.3% per year. Amgen is a growing business, which is encouraging. We would not expect to see insiders owning a large percentage of a US$147b company. Amgen announces 2024 first quarter dividend increase to $2.25 per share. Amgen names former Novartis exec James Bradner as chief scientific officer. Amgen is one of the worlds leading independent biotechnology companies. Amgen was named one of Americas Greatest Workplaces by Newsweek and Worlds Best Companies by TIME. Amgen Aims for Full Approval of Lumakras in NSCLC. Amgen CEO and Chairman Bob Bradway said in a release that Reese will be responsible for widening the companys use of AI and machine learning to the entire organization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. Amgen was named one of Americas Greatest Workplaces by Newsweek, one of Americas Climate Leaders by USA Today. U.S. FDA approves Amgens biosimilar version of J&Js psoriasis. Amgen announced that the U.S. FDA has granted priority review for an investigational Bispecific T-cell Engager (BiTE®) therapy. Amgen seeking approval for the use in small cell lung cancer patients with advanced disease. Amgen announces presentation of new data for patients with difficult-to-treat blood cancers. Findings will be shared at the American Society of Hematology Annual Meeting. Amgen to sponsor the irish open. amgen inc. amgn will be one of the 30 companies that comprise the Dow Jones Industrial Average. FDA Grants Priority Review to Amgens Tarlatamab Application for Advanced Small Cell Lung Cancer. Amgen plans to initiate an additional Phase 3 study of tarlatmab in first-line treatment of SCLC.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, company, Americas, FDA, stock, year, announces, and the most common words in the summary are: amgen, news, inc, stock, company, report, event, . One of the sentences in the summary was: stock outperforms competitors despite losses on the day - marketwatch.com.com.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #news #inc #stock #company #report #event.